July 7, 2015 – 11:08 am
The study was carried out by the UK Cystic Fibrosis Gene Therapy Consortium, a group of scientists and clinical teams from Imperial College London, the Universities of Oxford and Edinburgh. It involved 116 patients aged 12 and over who received monthly doses of either the therapy or the placebo for one year. Patients who received therapy showed a significant but modest benefit in lung function compared with those receiving a placebo. The trial is the first to show that repeated doses of gene therapy can have a meaningful effect on the disease, and change the lung function of patients. However, the team say more research is needed to improve the effectiveness before the therapy will be suitable for clinical use.
July 2, 2015 – 9:51 am
Creative Diagnostics, the global diagnostics service and product supplier, is pleased to announce its launch of custom antibody production service based on DNA immunization technology. This DNA immunization technology allows high success rate in generation of high-affinity antibodies recognizing difficult-to-express proteins in their native confirmation, such as GPCRs, ion channels and other multiple membrane spanning proteins. Genetic immunization is an attractive approach to generate antibodies because native proteins are expressed in vivo with normal post-transcriptional modifications, avoiding time-consuming and costly antigen isolation or synthesis. And DNA Immunization technology is a powerful tool to aid in custom antibody production against membrane proteins, other problematic antigens, as well as early DNA vaccine development studies. The unique antibody development approach involves direct immunization of host animals with plasmid DNA encoding the target protein of interest.
July 1, 2015 – 9:52 am
The first four patients in Canada’s only gene therapy trial for blindness say their vision has improved. All four of the Edmonton-area men have choroideremia, an inherited disorder that usually leads to legal blindness by the age of 40. Ken Ross, 43, underwent the procedure on his right eye on May 25, after what he describes as decades of “looking through a pinhole.” He says when doctors removed the bandage two days later the room seemed instantly brighter. And the view outside was better than ever.
June 26, 2015 – 9:37 am
The DNA vaccine segment of the animal vaccines market accounted for the highest growth in veterinary vaccine technology during 2014. Continued current innovation in the field seems likely to continue to drive this trend and thus diversify the animal vaccines market in general. DNA vaccines, particularly in the current animal vaccine market, offer various advantages over more traditional vaccination approaches. It enhances the immune systems response via an uptake in the overall quality and extent from the body, as well as carrying a stronger safety record than other applied veterinary approaches. It has been proven to combat both infectious diseases and malignant cancerous forms, breaking the tolerance these cancerous cells hold in the animal's body, which is a key focus for the vaccination development companies moving forward. With Dr Niranjan Sardesai of Inovio Pharmaceuticals declaring that the past ten years has been potentially the 'decade of DNA vaccines', perhaps exploitation of their cost-effectiveness will also contribute to a continued growth in CAGR.
June 22, 2015 – 9:24 am
SMA, the most common childhood disease of its type, arises from a recessive defect, meaning both mom and dad have to carry it and that each pregnancy brings a 25 percent risk of a baby born with a mutation in a gene called SMN1. Researchers have developed a Gene Therapy treatment for the disease which has shown to have significantly improved the condition of mice used in the experiments. In a small scale test on 8 infants the treatment has shown to improve or at least maintain their condition.
June 12, 2015 – 9:24 am
A team led by researchers at the Universidad Autónoma de Madrid in Spain recently published new data on a gene therapy for Friedreich’s ataxia based on the expression of the human frataxin gene from artificial systems. The study is entitled “Delivery of the 135 kb human frataxin genomic DNA locus gives rise to different frataxin isoforms” and was published in the journal Genomics. Friedreich’s ataxia is a rare inherited neurodegenerative disease characterized by progressive damage of the nervous system with degeneration of the spinal cord and peripheral nerves that leads to muscle weakness, sensory loss, balance deficits and lack of voluntary coordination of muscle movements. The disease is caused by a mutation in a gene called frataxin (FXN) that leads to a defective expression of the frataxin protein. Disease onset is usually during childhood or adolescence and the disorder leads to progressive disability, dependence on a wheelchair and reduced life expectancy. Currently, there is no effective approved treatment for the disease.
June 10, 2015 – 10:02 am
Novartis is well placed in the hot field of cancer immunotherapy, despite being behind rivals in developing immune system-boosting drugs known as checkpoint inhibitors, a top executive at the Swiss drugmaker said on Monday. Last year, Novartis bought CoStim Pharmaceuticals, giving it access to a so-called PD-1 checkpoint inhibitor, and in March this year it signed a deal with Aduro Biotech, securing access to a novel kind of immunotherapy approach called STING. As a result, the Swiss group is rapidly building an extensive presence in multiple immunotherapy approaches, opening the door to opportunities to create different drug cocktails.
Press Release: Ichor Partner Scancell Announces Update on SCIB1 Phase 1/2 Clinical Trial in Stage III and IV Melanoma Patients
June 3, 2015 – 10:35 am
SAN DIEGO, JUNE 2, 2015 -- Ichor Medical Systems, Inc. (Ichor) is pleased to announce that their partner Scancell Holdings plc (Scancell) presented updated and very encouraging data from the ongoing Phase 1/2 clinical trial of SCIB1, its DNA ImmunoBody® being developed for the treatment of patients with melanoma, at the American Society of Clinical Oncology (ASCO) meeting in Chicago. The trial is an open label, non-randomized study to characterize the safety and tolerability of SCIB1 administered using Ichor’s TriGridTM delivery system, as well as provide initial assessment of the ability of SCIB1 to delay or prevent disease recurrence in patients with Stage III/IV melanoma.
June 2, 2015 – 2:18 pm
Early trials of a new form of gene therapy may give hope to patients battling glioblastoma, the most deadly form of brain cancer. Called AdV-Tk therapy, the new treatment involves two steps. As the researchers explained it, the first step involves taking DNA from the herpes virus and injecting it into tumor cells, and then attacking those DNA-tagged cells with a powerful drug. In the second step, the drug helps spur the patient's immune systems to eliminate more of the cancer cells over time. All of the patients in the study had also undergone surgeries aimed at minimizing the tumor, the researchers noted
May 29, 2015 – 9:49 am
A new study indicates that scientists have inched closer to developing a vaccine to control blood pressure amid lingering issues with cardiovascular disease, including within the Hispanic/Latino community. Among Hispanics who've experienced a stroke, 72 percent had high blood pressure, compared to 66 percent in non-Hispanic whites. Osaka University in Japan has led the advancement in blood pressure vaccine, and the study's findings appeared in the journal Hypertension on Tuesday, May 26, in an article titled "Long-Term Reduction of High Blood Pressure by Angiotensin II DNA Vaccine in Spontaneously Hypertensive Rats.